DOCSLIB.ORG

Emedastine Difumarate 0.05%, and Loteprednol Etabonate 0.5&A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Emedastine Difumarate 0.05%, and Loteprednol Etabonate 0.5&A ORIGINAL ARTICLE Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study Rui-fen Liu, Xiao-xuan Wu, Xiao Wang, Jing Gao, Jun Zhou and Qi Zhao, MD Background: Allergic conjunctivitis (AC) is a disease of However, there was no statistical significance (p ࣙ 0.05) various agents that affects the physical and mental health shown among the treatment groups. There were no evident of children. Although the most effective therapy has not changes in VA and no clinically significant changes were ob- been found so far, it is essential to explore the considerable served in fundus oculi. therapeutic method. We compared the clinical efficacy of olopatadine, emedastine, loteprednol etabonate (LE), and Conclusion: Aer the treatment, the efficacy presented a vehicle for treating seasonal allergic conjunctivitis (SAC) in similar distribution among the trial groups. C 2016 The Au- Chinese children. thors International Forum of Allergy & Rhinology, published by ARSAAOA, LLC. Methods: Eighty cases of 160 eyes aged from 5 to 10 This is an open access article under the terms of the Cre- years with SAC were available and those subjects were ran- ative Commons Attribution-NonCommercial License, which domly distributed into 4 groups. Both their eyes received permits use, distribution and reproduction in any medium, olopatadine hydrochloride 0.1% twice a day, emedastine provided the original work is properly cited and is not used difumarate 0.05% twice a day, or LE 0.5% 4 times a day, for commercial purposes. respectively, whereas those of the control group received artificial tears (AT) 0.5% 3 times a day. This study was con- Key Words: ducted successfully and the observations were collected SAC; olopatadine hydrochloride; emedastine difumarate; before treatment and on day 8 (±1day)andday15(±2days) LE; vehicle; efficacy aerward. The principal measurement of efficacy was fo- cused on the signs and symptoms of the subjects, evaluated before and aer treatment, in addition to visual acuity (VA) How to Cite this Article: and fundus oculi. Liu R, Wu X, Wang X, Gao J, Zhou J, Zhao Q. Effi- cacy of olopatadine hydrochloride 0.1%, emedastine di- Results: On day 8 (±1day)andday15(±2 days), all the fumarate 0.05%, and loteprednol etabonate 0.5% for antiallergic agents were found to be more effective than Chinese children with seasonal allergic conjunctivitis: a vehicle (p < 0.05) in terms of all the symptoms and signs. randomized vehicle-controlled study. Int Forum Allergy Rhinol. 2016;XX:XXX-XXX. llergic conjunctivitis (AC) is a common allergic disease dust mites,9,12 and animal dander1,12 are the most common A that is present on the eye. The most evident case is sea- sensitizing agents. sonal allergic conjunctivitis (SAC).1,2 Patients are often also It is well known that the main current topical med- affected by allergic rhinitis,3–6 asthma,1,3,5,6 eczema,3,5 and ications available for the treatment of SAC consist food or drug allergies. Their parents and grandparents usu- of corticosteroids, such as loteprednol etabonate (LE); ally suffer from atopic-related diseases.7 Plant pollen,1,8–11 H-1antagonists, such as emedastine; and dual action agents, such as olopatadine; or artificial tears (AT), such as car- boxymethylcellulose sodium. Department of Ophthalmology, the Second Hospital Affiliated to In the past, olopatadine hydrochloride 0.1% has Dalian Medical University, Dalian, China been compared with emedastine difumarate 0.05%,13 LE Correspondence to: Qi Zhao, MD, Department of Ophthalmology, the 14 15,16 Second Hospital Affiliated to Dalian Medical University. 467, Zhongshan Rd, 0.5%, and vehicle, respectively. In addition, compar- Dalian, 116023, Liaoning Province, China; e-mail:[email protected] isons have also been done between emedastine difumarate 13 Potential conflict of interest: None provided. 0.05% and the placebo and between LE 0.5% and the 17 Received: 12 April 2016; Revised: 6 September 2016; Accepted: placebo. However, emedastine difumarate 0.05% and 18 November 2016 LE 0.5% have not been compared with each other. On the DOI: 10.1002/alr.21882 View this article online at wileyonlinelibrary.com. basis of that, this study compares their efficacy and then 1 International Forum of Allergy & Rhinology, Vol. , No. , xxxx 2016 Liu et al. TABLE 1. The scoring system of eye symptoms* TABLE 2. The scoring system of eye signs* Score Severity Description Score Severity Description 0 Absent Without any symptoms 0 Absent Without any symptoms 1 Slight Slight symptoms, patients having little or 1 Mild Mild signs slight feeling 2 Moderate Moderate signs 2 Mild Mild symptoms, patients feeling discomfort 3 Severe Severe signs but being capable of tolerating 3 Moderate Moderate symptoms, patients being difficult *The main signs include conjunctival papilla, follicle, conjunctival congestion, edema. to tolerate 4 Severe Severe symptoms, patients being incapable of tolerating of symptoms (0 = absent, 1 = mild, 2 = moderate, and 3 = severe). The evaluation of grading is shown in Table 2. *The main symptoms include itching, photophobia, blinking. The measurement standard of the symptoms and signs was evaluated by the same investigator through the direct ques- respectively compares them with olopatadine 0.1%. We tioning of children or observation. All the efficacy variables mainly focus on comparing olopatadine, emedastine, LE, were assessed for both eyes at each visit. and vehicle (AT) in the temporary treatment of Chinese Exclusion criteria: aged ࣙ11 years or ࣘ4 years old. Chil- children with SAC in similar living environments. dren who suffered from refractive errors, those whose best corrected VA was ࣘ0.4, or those children who suffered from keratoconus were also excluded. In addition, those Patients and methods who had received an ocular operation or who wore intraoc- Study design ular lens or contact lenses were excluded. Outpatients with > This was a 3-visit, prospective, single-blind, randomized, intraocular pressure 21 mm Hg in any each eye were also placebo-controlled, single-center study in the Ophthalmol- excluded. Further exclusions were children using any antial- ogy Department of the Second Hospital affiliated with lergic medication (such as H-1 antihistamines, mast cell sta- Dalian Medical University. There were 90 subjects (180 bilizers, eye drops of corticosteroid, nasal spray, or general eyes) of SAC primarily in the study. We finally had 80 chil- drugs) in the 30 days before testing. Using any drugs that dren of 160 eyes (48 cases of boys, 32 girls, ranging from 5 cause eye diseases, any anti-allergic treatment, other ocular to 10 years old, with an average age of 6.33 ± 1.89 years); diseases and systemic diseases, other active eye diseases and another 10 cases were excluded due to loss to follow-up. diseases of the heart, brain, liver, kidney, or hematopoietic Registration of children with SAC took place from July system in the last 1 month also were disqualified in outpa- 2015 through November 2015 in our study. Before study tient selection. Those who were unable to assess the efficacy procedures were conducted, written informed consent was or failed to offer information completely were excluded. obtained from all parents/guardians. The study protocol Finally, those who were not using the ophthalmic solution was approved by the Ethics Committee of Second Hospital regularly, or not following-up, thus affecting the curative affiliated with Dalian Medical University. effect, were also excluded. Study subjects Study procedures The following were all the criteria of our study: the age The subjects were distributed into 4 groups by random of children ranging from 5 to 10 years old; stopping using number table; on average, 20 cases in each group. Children other anti-allergy agents for at least 30 days14; with grade were randomly assigned to receive topical administration 3 or higher in symptoms and grade 2 or higher in signs at of 1 drop of olopatadine hydrochloride (HCL) 0.1% oph- visit 1(the first study visit). All the variables with respect to thalmic solution (Patanol) twice per day (BID) (olopatadine baseline were similar in each group. Changes of symptoms solution group); 1 drop of emedastine difumarate 0.05% were graded on a 0 to 4 scale and increased by 0.5 incre- ophthalmic solution (Emadine) BID (emedastine solution ments; the higher the points the more evident the symp- group); LE 0.5% ophthalmic suspension (Lotemax) 4 times toms were. Ocular symptoms were graded on a 0 to 4 scale per day (QID) (LE solution group); or AT 0.5% (Refresh (0 = absent, 1 = slight, 2 = mild, 3 = moderate, and 4 Plus) 3 times per day (TID) (vehicle group); in both eyes for = severe).6 The main symptoms include itching, photopho- 14 ± 2 days. Ophthalmic solution was dropped into the bia, foreign body sensation, and blinking. The assessment fornix conjunctivae inferior for 1 drop in each eye. of grade is shown in Table 1. The main signs include papilla A visit 1 (day 0), on the first day of the study, all in upper and lower of palpebral conjunctiva, follicle, con- patients were questioned about ethnicity; systemic allergic junctival congestion, and conjunctival edema. Ocular signs conditions or not, and family members (father, mother, were graded on a 0 to 3 points, similar to the definition grandfather, grandmother, etc.) with atopic history International Forum of Allergy & Rhinology, Vol. , No. , xxxx 2016 2 Three treatments for SAC in Chinese children including suffering from allergic rhinitis, asthma, eczema, statistically significant (p < 0.05) between the study groups dermatitis, food allergy, and drug allergy. Moreover, they and the placebo group. There were no statistically signif- were asked whether, in their living environment, there icant differences among the treatment groups (p > 0.05).
Load more

Recommended publications
  • Inhibition of Histamine-Induced Human Conjunctival Epithelial Cell Responses by Ocular Allergy Drugs
    LABORATORY SCIENCES Inhibition of Histamine-Induced Human Conjunctival Epithelial Cell Responses by Ocular Allergy Drugs John M. Yanni, PhD; Lori K. Weimer, BA; Najam A. Sharif, PhD; Shou X. Xu, MS; Daniel A. Gamache, PhD; Joan M. Spellman, MS Objective: To evaluate the effects of topical ocular drugs secretion (50% inhibitory concentration, 1.7-5.5 nmol/L) with histamine H1-antagonist activity on histamine- than predicted from binding data, while antazoline and stimulated phosphatidylinositol turnover and interleu- pheniramine were far less potent (20- to 140-fold) in func- kin (IL) 6 and IL-8 secretion from human conjunctival tional assays. Levocabastine (dissociation constant, 52.6 epithelial cells. nmol/L) exhibited greater functional activity (50% in- hibitory concentration, 8-25 nmol/L) than either antazo- Methods: Primary human conjunctival epithelial cell cul- line or pheniramine. tures were stimulated with histamine in the presence or ab- sence of test drugs. Phosphatidylinositol turnover was quan- Conclusions: Histamine-stimulated phosphatidylino- tified by ion exchange chromatography and cytokine con- sitol turnover and cytokine secretion by human conjunc- tentofsupernatantsbyenzyme-linkedimmunosorbentassay. tival epithelial cells are attenuated by compounds with H1-antagonist activity. However, antihistaminic po- Results: Antazoline hydrochloride, emedastine difuma- tency alone does not predict anti-inflammatory poten- rate, levocabastine hydrochloride, olopatadine hydro- tial. Olopatadine, emedastine, and levocabastine were no- chloride, and pheniramine maleate attenuated histamine- tably more potent than pheniramine and antazoline. stimulated phosphatidylinositol turnover and IL-6 and IL-8 secretion. Emedastine was the most potent in li- Clinical Relevance: Selected topical ocular drugs with gand binding, phosphatidylinositol turnover, and IL-6 se- antihistaminic activity may offer therapeutic advan- cretion, with dissociation constant and 50% inhibitory tages to patients with allergic conjunctivitis by inhibit- concentrations of 1-3 nmol/L.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Emadine, INN-Emedastine
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT EMADINE 0.5 mg/ml, eye drops, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution contains emedastine 0.5 mg (as difumarate) Excipient with known effect Benzalkonium chloride 0.1 mg/ml For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Eye drops, solution. Clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Symptomatic treatment of seasonal allergic conjunctivitis. 4.2 Posology and method of administration EMADINE has not been studied in clinical trials beyond six weeks. Posology The dose is one drop of EMADINE to be applied to the affected eye(s) twice daily. When used with other ophthalmic medicines, an interval of ten minutes should be allowed between applications of each medicinal product. Eye ointments should be administered last. Elderly population EMADINE has not been studied in elderly patients older than 65 years, and therefore its use is not recommended in this population. Paediatric population EMADINE may be used in paediatric patients (3 years of age and older) at the same posology as in adults. Hepatic and Renal impairment Use EMADINE has not been studied in these patients and therefore, its use is not recommended in this population. Method of administration For ocular use. 2 To prevent contamination of the dropper tip and solution, care should be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle. After cap is removed, if tamper evident snap collar is loose, remove before using product.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • A Practical Approach to Management of Allergic Eye Conditions in Children
    Volume 6 No. 3, September 2010 Review Article A Practical Approach to Management of Allergic Eye Conditions in Children Dexter Yu-Lung LEUNG Hong Kong Eye Hospital; Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong; and Hong Kong Ophthalmological Society, Hong Kong Introduction In USA, expenditure related to ocular prescription medication rose from US$6 million in early 1990s to While nasal allergy all along has been important in >US$200 million in the new millennium, projecting an allergy research, ocular allergy is now increasingly annual growth of 25% per year in USA.7 recognized as a distinct symptoms-and-signs complex that imposes significant disease burden with reduction of quality of life of patients. Allergic conjunctivitis is Classification highly prevalent in Hong Kong and has a close epidemiologic relationship with allergic rhinitis. The emphasis of this article will also be on what a paediatrician can do prior to the point of referral: recognition of the ocular symptoms, recognition of potential sight-threatening situations, and effective initial treatment. Disease burden While we are still awaiting published evidence for official incidence of ocular allergy in Hong Kong, a recent survey from the Eye Institute of the University of Hong Kong, conducted during May and June 2009 on 1,000 parents with children less than 12 years old in Hong Kong, has estimated that approximately 30% SAC and PAC are more common, and while they are of children suffered from eye allergy.1 symptomatic, they are less likely to result in long term ocular complications. VKC and AKC are rarer, more The incidence of ocular allergy varies in different chronic but are potentially associated with severe geographical regions and tends to be more common blinding ocular complications.
    [Show full text]
  • North Dakota Department of Human Services North Dakota Medicaid Preferred Drug List with Prior Authorization Criteria Effective
    NORTH DAKOTA DEPARTMENT OF HUMAN SERVICES NORTH DAKOTA MEDICAID EFFECTIVE PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA January 1, 2017 This is not an all-inclusive list of available covered drugs requiring prior authorization. Only PDL Version 2017.1b managed categories are included. Refer to cover page for complete list of rules governing this PDL. Visit http://www.hidesigns.com/ndmedicaid for more information on prior authorization for medications not found in this list. Prior authorization for a non-preferred agent in any category will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient at a therapeutic dose that resulted in a partial response with a documented intolerance. Prior authorization criteria for non-preferred agents apply in addition to the general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc. Refer to http://www.hidesigns.com/ndmedicaid for applicable quantity limits and therapeutic duplication edits. Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified. The use of pharmaceutical samples will not be considered when evaluating the member’s medical condition or prior prescription history for drugs that require prior authorization. This is not an all-inclusive list of medications that require PA. For more information visit http://www.hidesigns.com/ndmedicaid. This PDL is subject to change. Preferred positions and criteria will go into effect when an SRA is executed.
    [Show full text]
  • National PBM Drug Monograph Epinastine (Elestat™) May 2004 VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel
    National PBM Drug Monograph Epinastine (Elestat™) May 2004 VHA Pharmacy Benefits Management Strategic Healthcare Group and the Medical Advisory Panel EXECUTIVE SUMMARY • Antihistamine ophthalmic drops provide quick relief from allergic conjunctivitis (AC) symptoms such as itching and redness, without the potential adverse effects associated with systemic absorption. • Epinastine is the fourth ophthalmic antihistamines/mast cell stabilizer approved for the itching associated with AC. Other ophthalmic preparations for allergic conjunctivitis include antihistamines, mast cell stabilizers, nonsteroidal anti-inflammatory agents (NSAIDs), corticosteroids, decongestants, and decongestant/antihistamines. • An ideal agent would offer improved efficacy and safety, reduce polypharmacy as a combination product or through replacing oral agents, and provide evidence for chronic AC prevention. INTRODUCTION1 The purposes of this monograph are to (1) evaluate the available evidence of safety, tolerability, efficacy, cost, and other pharmaceutical issues that would be relevant to evaluating epinastine ophthalmic solution for possible addition to the VA National Formulary (VANF); (2) define its role in therapy; and (3) identify parameters for its rational use in the VA. PHARMACOLOGY/PHARMACOKINETICS1, 2 Antihistamines are receptor antagonists used to avoid the inflammatory effects of histamine. Taken orally, these agents have been shown to be effective for treating allergic symptoms such as pruritis (itching). Epinastine in particular has been found to have a rapid onset of action.3 Topical antihistamine eye drops provide relief from ocular symptoms without systemic absorption or related adverse events, allowing for the combination of oral and topical agents when indicated. Ophthalmic antihistamine/mast cell stabilizers such as epinastine combine H1-receptor actions to block ocular itching and redness with H2-receptor affinity.
    [Show full text]
  • Therapeutic Drug Class
    EFFECTIVE Version Department of Vermont Health Access Updated: 02/16/17 Pharmacy Benefit Management Program /2016 Vermont Preferred Drug List and Drugs Requiring Prior Authorization (includes clinical criteria) The Commissioner for Office of Vermont Health Access shall establish a pharmacy best practices and cost control program designed to reduce the cost of providing prescription drugs, while maintaining high quality in prescription drug therapies. The program shall include: "A preferred list of covered prescription drugs that identifies preferred choices within therapeutic classes for particular diseases and conditions, including generic alternatives" From Act 127 passed in 2002 The following pages contain: • The therapeutic classes of drugs subject to the Preferred Drug List, the drugs within those categories and the criteria required for Prior Authorization (P.A.) of non-preferred drugs in those categories. • The therapeutic classes of drugs which have clinical criteria for Prior Authorization may or may not be subject to a preferred agent. • Within both of these categories there may be drugs or even drug classes that are subject to Quantity Limit Parameters. Therapeutic class criteria are listed alphabetically. Within each category the Preferred Drugs are noted in the left-hand columns. Representative non- preferred agents have been included and are listed in the right-hand column. Any drug not listed as preferred in any of the included categories requires Prior Authorization. GHS/Change Healthcare GHS/Change Healthcare GHS/Change Healthcare Sr. Account Manager: PRESCRIBER Call Center: PHARMACY Call Center: PA Requests PA Requests Michael Ouellette, RPh Tel: 1-844-679-5363; Fax: 1-844-679-5366 Tel: 1-844-679-5362 Tel: 802-922-9614 Note: Fax requests are responded to within 24 hrs.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Allergic Conjunctivitis and H Antihistamines
    Allergic Conjunctivitis and H1 Antihistamines A del Cuvillo,1 J Sastre,2,3 J Montoro,4 I Jáuregui,5 I Dávila,6 M Ferrer,7 J Bartra,8,3 J Mullol,9,3 A Valero8,3 1 Clínica Dr. Lobatón, Cádiz, Spain 2 Servicio de Alergia, Fundación Jiménez Díaz, Madrid, Spain 3 Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) 4 Unidad de Alergia, Hospital La Plana, Villarreal (Castellón), Spain 5 Servicio de Alergología, Hospital de Basurto, Bilbao, Spain 6 Servicio de Inmunoalergia, Hospital Universitario, Salamanca, Spain 7 Departamento de Alergia e Inmunología Clínica, Clínica Universidad de Navarra, Pamplona, Spain 8 Unitat d’Al.lèrgia, Servei de Pneumologia i Al.lèrgia Respiratòria, Hospital Clinic (ICT), Barcelona, Spain 9 Unitat de Rinologia & Clínica de l’Olfacte, Servei d’Oto-rino-laringologia, Hospital Clínic Immunoal.lèrgia Respiratòria Clínica i Experimental, IDIBAPS. Barcelona, Spain ■ Abstract Allergic conjunctivitis is the most common form of ophthalmological allergy. Eye symptoms are one of the main and most frequent reasons for consultation among patients with allergic rhinoconjunctivitis, which in turn is the most common reason for visiting the allergologist, according to the Alergológica 2005 study. Itching is the key symptom of allergic conjunctivitis, and its relief is the principal objective of the broad range of treatment options available. Topical antihistamines with multiple actions (mast cell stabilization, and antiinfl ammatory and antihistaminic actions) are probably the best treatment option, thanks to their rapid action, safety and convenience of use. However, oral antihistamines (preferentially second generation drugs) can also play an important role, since they are of established effi cacy and offer adequate treatment of the nasal symptoms that tend to accompany the ocular manifestations of allergic rhinoconjunctivitis.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]